Safety and effectiveness of mirogabalin for CIPN induced by nab-paclitaxel in patients with pancreatic cancer

被引：0
|
作者：
Saito, Kei [1 ]
Nakai, Yousuke [1 ,2 ]
Ishigaki, Kazunaga [1 ]
Takahara, Naminatsu [1 ]
Suzuki, Tatsunori [1 ]
Hakuta, Ryunosuke [1 ,2 ]
Saito, Tomotaka [1 ]
Hamada, Tsuyoshi [1 ]
Mizuno, Suguru [1 ]
Kogure, Hirofumi [1 ]
Fujishiro, Mitsuhiro [1 ]
机构：
[1] Univ Tokyo, Dept Gastroenterol, Grad Sch Med, Tokyo, Japan
[2] Univ Tokyo, Dept Endoscopy & Endoscop Surg, Grad Sch Med, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.262
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P21-17
引用
下载
收藏
页码：S520 / S520
页数：1
相关论文
共 50 条
  • [21] Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study
    Ohwada, Sae
    Todaka, Akiko
    Nakase, Hiroshi
    Shirasu, Hiromichi
    Kawakami, Takeshi
    Hamauchi, Satoshi
    Tsushima, Takahiro
    Yokota, Tomoya
    Onozawa, Yusuke
    Yasui, Hirofumi
    Yamazaki, Kentaro
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1106 - 1116
  • [22] Predictors of vulnerability to nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
    Iede, Kiyotsugu
    Yamada, Terumasa
    Tominaga, Shusei
    ANNALS OF ONCOLOGY, 2023, 34 : S1453 - S1453
  • [23] Survival of patients with advanced pancreatic cancer is increased by nab-paclitaxel plus gemcitabine
    Nature Reviews Gastroenterology & Hepatology, 2013, 10 (12) : 695 - 695
  • [24] Gemcitabine and nab-paclitaxel in patients with unresectable/borderline resectable pancreatic cancer.
    Thapaliya, P.
    Kundranda, M. N.
    Curtis, K. K.
    Callister, M. D.
    Ashman, J. B.
    Collins, J.
    Moss, A.
    Mekeel, K. L.
    Silva, A. C.
    Borad, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer
    Martina Catalano
    Giuseppe Aprile
    Raffaele Conca
    Roberto Petrioli
    Monica Ramello
    Giandomenico Roviello
    Scientific Reports, 12
  • [26] The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer
    Catalano, Martina
    Aprile, Giuseppe
    Conca, Raffaele
    Petrioli, Roberto
    Ramello, Monica
    Roviello, Giandomenico
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [27] Congestive Heart Failure Secondary to Gemcitabine Nab-paclitaxel in Patients with Pancreatic Cancer
    John, Preethi
    Butler, Harriet
    Saif, Muhammad Wasif
    ANTICANCER RESEARCH, 2014, 34 (12) : 7267 - 7270
  • [28] Neo-adjuvant treatment in patients with pancreatic cancer with nab-paclitaxel and gemcitabine
    Pomillo, A.
    Santoro, M.
    Iuliano, E.
    Luci, M.
    Perricelli, A.
    Iuliano, F.
    Mazzulla, M. F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Effectiveness of CA 19.9 in predicting prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine
    Mariani, S.
    Soro, P.
    Liscia, N.
    Balconi, F.
    Camera, S.
    Donisi, C.
    Impera, V.
    Musio, F.
    Persano, M.
    Pireddu, A.
    Pretta, A.
    Tolu, S.
    Pusceddu, V.
    Lai, E.
    Faloppi, L.
    Demurtas, L.
    Ziranu, P.
    Puzzoni, M.
    Scartozzi, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 63 - 63
  • [30] Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study
    Catalano, Martina
    Roviello, Giandomenico
    Conca, Raffaele
    D'Angelo, Alberto
    Palmieri, Valeria Emma
    Panella, Benedetta
    Petrioli, Roberto
    Ianza, Anna
    Nobili, Stefania
    Mini, Enrico
    Ramello, Monica
    CURRENT CANCER DRUG TARGETS, 2020, 20 (11) : 887 - 895
12345